HUP0303164A2 - Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents
Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0303164A2 HUP0303164A2 HU0303164A HUP0303164A HUP0303164A2 HU P0303164 A2 HUP0303164 A2 HU P0303164A2 HU 0303164 A HU0303164 A HU 0303164A HU P0303164 A HUP0303164 A HU P0303164A HU P0303164 A2 HUP0303164 A2 HU P0303164A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- atom
- alkyl
- general formula
- heterocyclic
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003246 quinazolines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004434 sulfur atom Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- -1 amino- Chemical class 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
A találmány tárgyát az (I) általános képletű vegyületek képezik, ahol:R1 jelentése a következő csoportok valamelyike: hidrogénatom, amino-,alkil-, alkenil-, aminoalkil-, aril-, arilalkil-csoport,heterociklusos csoport vagy cikloalkilcsoport, amely lehethelyettesített, W jelentése oxigénatom, kénatom vagy =N-R' általánosképletű csoport, Y jelentése oxigénatom, kénatom, -NH- vagy -N-(1-6szénatomos alkil)-csoport, Z jelentése oxigénatom, kénatom vagy -NR7általános képletű csoport, n értéke 1-től 8-ig terjedő egész szám, Z1jelentése -CR8R9 általános képletű csoport, A jelentése aromás vagynemaromás, heterociklusos vagy nem-heterociklusos gyűrűrendszer, mértéke 0- tól 7-ig terjedő egész szám, az R2 csoport(ok) jelentéseelőnyösen alkilcsoport vagy halogénatom, R3 jelentése hidrogénatom,alkil-, alkenil-, alkinil-csoport vagy (a) képletű csoport, valamintlehetségesek még a fentiek racém formái, izomerjei, N-oxidjai ésgyógyászatilag elfogadható sói, valamint az ezeket tartalmazógyógyászati termékek, amelyek alkalmasak a 13-típusú mátrixmetalloproteáz specifikus gátlására. A találmány kiterjed a vegyületekelőállítására is. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26866101P | 2001-02-14 | 2001-02-14 | |
PCT/EP2002/001979 WO2002064572A1 (en) | 2001-02-14 | 2002-02-11 | Quinazolines as mmp-13 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0303164A2 true HUP0303164A2 (hu) | 2004-01-28 |
Family
ID=23023949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0303164A HUP0303164A2 (hu) | 2001-02-14 | 2002-02-11 | Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények |
Country Status (30)
Country | Link |
---|---|
US (1) | US20020193377A1 (hu) |
EP (1) | EP1368324A1 (hu) |
JP (1) | JP2004523546A (hu) |
KR (1) | KR20030074827A (hu) |
CN (1) | CN1537105A (hu) |
AP (1) | AP2003002841A0 (hu) |
AR (1) | AR032676A1 (hu) |
BG (1) | BG108091A (hu) |
BR (1) | BR0207268A (hu) |
CA (1) | CA2437122A1 (hu) |
CZ (1) | CZ20032142A3 (hu) |
EA (1) | EA200300792A1 (hu) |
EC (1) | ECSP034730A (hu) |
EE (1) | EE200300384A (hu) |
HU (1) | HUP0303164A2 (hu) |
IL (1) | IL157109A0 (hu) |
IS (1) | IS6886A (hu) |
MA (1) | MA26994A1 (hu) |
MX (1) | MXPA03007248A (hu) |
NO (1) | NO20033593D0 (hu) |
OA (1) | OA12550A (hu) |
PA (1) | PA8539401A1 (hu) |
PE (1) | PE20021005A1 (hu) |
PL (1) | PL367396A1 (hu) |
SK (1) | SK10012003A3 (hu) |
SV (1) | SV2003000876A (hu) |
TN (1) | TNSN03045A1 (hu) |
UY (1) | UY27173A1 (hu) |
WO (1) | WO2002064572A1 (hu) |
ZA (1) | ZA200306008B (hu) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DOP2002000334A (es) * | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz |
PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
WO2003032999A1 (en) | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkyne matrix metalloproteinase inhibitors |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
AU2002249275A1 (en) * | 2002-03-08 | 2003-09-22 | Warner-Lambert Company Llc | Oxo azabicyclic compounds |
US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
JP2006502113A (ja) * | 2002-07-17 | 2006-01-19 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | マトリックス・メタロプロテイナーゼ−13アロステリック阻害剤と、セレコキシブ又はバルデコキシブでないシクロオキシゲナーゼ−2選択的阻害剤との複合体 |
MXPA05000754A (es) * | 2002-07-17 | 2005-04-19 | Warner Lambert Co | Combinacion de un inhibidor carboxilico alosterico de la metaloproteinasa de matriz-13 con celecoxib o valdecoxib. |
EP1536786A1 (en) * | 2002-07-17 | 2005-06-08 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
AU2003281170A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Pharmaceutical compostions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2 |
AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
BR0313384A (pt) | 2002-08-13 | 2005-07-12 | Warner Lambert Co | Derivados de cromona como inibidores de metaloproteinases de matriz |
JP2006501215A (ja) | 2002-08-13 | 2006-01-12 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体 |
WO2004014375A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
WO2004014908A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
AU2003250465A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
AU2003250475A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
AU2003250471A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
AU2003249531A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
CA2492019A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Isoquinoline derivatives as matrix metalloproteinase inhibitors |
WO2004014384A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
CA2508792C (en) * | 2002-12-06 | 2013-02-05 | Affinium Pharmaceuticals, Inc. | Heterocyclic compounds, methods of making them and their use in therapy |
JP4619795B2 (ja) * | 2002-12-31 | 2011-01-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | ホスファターゼのインヒビター |
US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
EP1680125A1 (en) * | 2003-07-02 | 2006-07-19 | Warner-Lambert Company LLC | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
WO2005019188A1 (ja) * | 2003-08-22 | 2005-03-03 | Takeda Pharmaceutical Company Limited | 縮合ピリミジン誘導体およびその用途 |
US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
DE10360835A1 (de) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
EP1746999B1 (en) * | 2004-05-06 | 2011-11-16 | Warner-Lambert Company LLC | 4-phenylamino-quinazolin-6-yl-amides |
DK1860098T3 (da) * | 2005-03-16 | 2012-12-17 | Toyama Chemical Co Ltd | Nyt anthranilsyrderivat eller salt deraf |
WO2008009122A1 (en) | 2006-07-20 | 2008-01-24 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as fab i inhibitors |
EP2125802A4 (en) | 2007-02-16 | 2014-08-20 | Debiopharm Int Sa | SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS |
CN101622234B (zh) * | 2007-03-06 | 2013-08-07 | 诺瓦提斯公司 | 适于治疗炎性或变应性病症的二环有机化合物 |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8703777B2 (en) | 2008-01-04 | 2014-04-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
AU2009260503B2 (en) | 2008-05-27 | 2014-03-27 | The Board Of Regents Of The University Of Texas System | Wnt protein signalling inhibitors |
WO2010132815A1 (en) | 2009-05-15 | 2010-11-18 | The Research Foundation Of State University Of New York | Curcumin analogues as zinc chelators and their uses |
EP2266984A1 (en) * | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis |
US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
WO2013019682A1 (en) * | 2011-07-29 | 2013-02-07 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
FR2991578B1 (fr) * | 2012-06-06 | 2019-12-27 | L'oreal | Composes pour application anti-age et peau seche |
SI2861608T1 (sl) | 2012-06-19 | 2019-08-30 | Debiopharm International Sa | Derivati predzdravila (E)-N-metil-N-((3-metilbenzofuran-2-IL)metil)- 3-(7-okso-5,6,7,8-tetrahidro-1 ,8-nafthiridin-3-il)akrilamid |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
ITMI20130646A1 (it) * | 2013-04-19 | 2014-10-20 | Univ Bologna Alma Mater | Composti chinazolindionici con attività inibente sulle sirtuine |
CN103664767A (zh) * | 2013-12-06 | 2014-03-26 | 常熟市联创化学有限公司 | 一种2,6-吡啶二甲酸的制备方法 |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
EP3180337B1 (en) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives |
EP3180345B1 (en) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders |
WO2016023831A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives |
EP3180340B1 (en) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
WO2016039408A1 (ja) * | 2014-09-11 | 2016-03-17 | 武田薬品工業株式会社 | 複素環化合物 |
CA3014541A1 (en) | 2016-02-26 | 2017-08-31 | Debiopharm International S.A. | Medicament for treatment of diabetic foot infections |
CN109640999A (zh) | 2016-06-24 | 2019-04-16 | 无限药品股份有限公司 | 组合疗法 |
CN111116494B (zh) * | 2019-12-31 | 2022-08-16 | 江苏中旗科技股份有限公司 | 一类含喹唑啉二酮结构的酰胺类化合物、其制备方法与应用 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU119879A1 (ru) * | 1958-10-21 | 1958-11-30 | В.М. Нестеров | Способ получени 1,3-диметил-4-имино-5,-изонитрозоурацила |
CA762455A (en) * | 1962-03-22 | 1967-07-04 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Pyrido-pyrimidines |
CA764962A (en) * | 1962-03-22 | 1967-08-08 | Ohnacker Gerhard | Pyrido-pyrimidines |
DK408574A (hu) * | 1973-09-06 | 1975-05-05 | Ciba Geigy Ag | |
DE3502590A1 (de) * | 1985-01-26 | 1986-07-31 | Gödecke AG, 1000 Berlin | 5-alkoxy-pyrido(4,3-d)pyrimidin-derivate, verfahren zu deren herstellung und deren verwendung |
DE3502742A1 (de) * | 1985-01-28 | 1986-07-31 | Gödecke AG, 1000 Berlin | 5-oxo-pyrido(4,3-d)pyrimidin-derivate, verfahren zu deren herstellung und deren verwendung |
GB9214053D0 (en) * | 1992-07-02 | 1992-08-12 | Ici Plc | Heterocyclic amides |
EP0621037B1 (de) * | 1993-04-23 | 1999-07-07 | Hoechst Aktiengesellschaft | Pyrido-pyrimidindione, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US5281602A (en) * | 1993-04-23 | 1994-01-25 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6-substituted 5,6,7,8-tetrahydro-pyrido[4,3-D]pyrimidin-4(3H)-ones |
KR100423590B1 (ko) * | 1995-08-02 | 2004-09-10 | 호따. 우리아치에씨아. 에세. 아. | 항진균활성을갖는신규피리미돈유도체 |
ZA974030B (en) * | 1996-05-15 | 1998-02-19 | Bayer Ag | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids. |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
NZ334897A (en) * | 1996-12-09 | 2001-02-23 | Warner Lambert Co | Medicaments for treating and preventing heart failure and ventricular dilatation |
WO1999064400A1 (en) * | 1998-06-12 | 1999-12-16 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
PA8539301A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
US20030114666A1 (en) * | 2001-06-19 | 2003-06-19 | Ellsworth Edmund Lee | Antibacterial agents |
AU2003265242A1 (en) * | 2002-05-23 | 2003-12-22 | Cytokinetics, Inc. | Compounds, compositions, and methods |
AU2003281170A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Pharmaceutical compostions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2 |
WO2004007025A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
MXPA05000754A (es) * | 2002-07-17 | 2005-04-19 | Warner Lambert Co | Combinacion de un inhibidor carboxilico alosterico de la metaloproteinasa de matriz-13 con celecoxib o valdecoxib. |
WO2004006914A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
AU2003250475A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
BR0313384A (pt) * | 2002-08-13 | 2005-07-12 | Warner Lambert Co | Derivados de cromona como inibidores de metaloproteinases de matriz |
CA2494048A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors |
AU2003250465A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
CA2492019A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Isoquinoline derivatives as matrix metalloproteinase inhibitors |
AU2003253149A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors |
AU2003250466A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
WO2004014388A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors |
US7439249B2 (en) * | 2002-12-31 | 2008-10-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatases |
AU2004249120B2 (en) * | 2003-05-23 | 2008-07-24 | Glaxosmithkline | Guanidino-substituted quinazolinone compounds as MC4-R agonists |
DE602004021611D1 (de) * | 2003-09-19 | 2009-07-30 | Gilead Sciences Inc | Azachinolinolphosphonatverbindungen als integraseinhibitoren |
-
2002
- 2002-02-08 PA PA20028539401A patent/PA8539401A1/es unknown
- 2002-02-11 OA OA1200300200A patent/OA12550A/en unknown
- 2002-02-11 CZ CZ20032142A patent/CZ20032142A3/cs unknown
- 2002-02-11 PL PL02367396A patent/PL367396A1/xx not_active Application Discontinuation
- 2002-02-11 SK SK1001-2003A patent/SK10012003A3/sk unknown
- 2002-02-11 CA CA002437122A patent/CA2437122A1/en not_active Abandoned
- 2002-02-11 CN CNA028050142A patent/CN1537105A/zh active Pending
- 2002-02-11 JP JP2002564505A patent/JP2004523546A/ja not_active Abandoned
- 2002-02-11 AP APAP/P/2003/002841A patent/AP2003002841A0/en unknown
- 2002-02-11 EE EEP200300384A patent/EE200300384A/xx unknown
- 2002-02-11 IL IL15710902A patent/IL157109A0/xx unknown
- 2002-02-11 BR BR0207268-8A patent/BR0207268A/pt not_active IP Right Cessation
- 2002-02-11 WO PCT/EP2002/001979 patent/WO2002064572A1/en not_active Application Discontinuation
- 2002-02-11 HU HU0303164A patent/HUP0303164A2/hu unknown
- 2002-02-11 EP EP02722137A patent/EP1368324A1/en not_active Withdrawn
- 2002-02-11 MX MXPA03007248A patent/MXPA03007248A/es unknown
- 2002-02-11 KR KR10-2003-7010659A patent/KR20030074827A/ko not_active Application Discontinuation
- 2002-02-11 EA EA200300792A patent/EA200300792A1/ru unknown
- 2002-02-13 UY UY27173A patent/UY27173A1/es not_active Application Discontinuation
- 2002-02-13 US US10/075,954 patent/US20020193377A1/en not_active Abandoned
- 2002-02-13 PE PE2002000118A patent/PE20021005A1/es not_active Application Discontinuation
- 2002-02-13 SV SV2002000876A patent/SV2003000876A/es not_active Application Discontinuation
- 2002-02-13 AR ARP020100470A patent/AR032676A1/es not_active Application Discontinuation
-
2003
- 2003-07-08 TN TNPCT/EP2002/001979A patent/TNSN03045A1/en unknown
- 2003-07-24 IS IS6886A patent/IS6886A/is unknown
- 2003-08-04 ZA ZA2003/06008A patent/ZA200306008B/en unknown
- 2003-08-12 MA MA27274A patent/MA26994A1/fr unknown
- 2003-08-13 BG BG108091A patent/BG108091A/xx unknown
- 2003-08-13 NO NO20033593A patent/NO20033593D0/no not_active Application Discontinuation
- 2003-08-13 EC EC2003004730A patent/ECSP034730A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PL367396A1 (en) | 2005-02-21 |
EP1368324A1 (en) | 2003-12-10 |
MXPA03007248A (es) | 2005-02-14 |
NO20033593L (no) | 2003-08-13 |
PE20021005A1 (es) | 2002-11-27 |
MA26994A1 (fr) | 2004-12-20 |
CA2437122A1 (en) | 2002-08-22 |
EE200300384A (et) | 2003-12-15 |
IL157109A0 (en) | 2004-02-08 |
JP2004523546A (ja) | 2004-08-05 |
BG108091A (en) | 2004-12-30 |
OA12550A (en) | 2006-06-05 |
AP2003002841A0 (en) | 2003-09-30 |
SV2003000876A (es) | 2003-08-19 |
CZ20032142A3 (cs) | 2004-12-15 |
PA8539401A1 (es) | 2002-10-28 |
CN1537105A (zh) | 2004-10-13 |
ECSP034730A (es) | 2003-12-01 |
SK10012003A3 (sk) | 2004-09-08 |
WO2002064572A1 (en) | 2002-08-22 |
BR0207268A (pt) | 2005-03-15 |
US20020193377A1 (en) | 2002-12-19 |
NO20033593D0 (no) | 2003-08-13 |
IS6886A (is) | 2003-07-24 |
TNSN03045A1 (en) | 2005-12-23 |
EA200300792A1 (ru) | 2004-02-26 |
KR20030074827A (ko) | 2003-09-19 |
ZA200306008B (en) | 2005-01-26 |
AR032676A1 (es) | 2003-11-19 |
UY27173A1 (es) | 2002-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0303164A2 (hu) | Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0204245A2 (hu) | Új N-aza-biciklo-amid-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
NZ532494A (en) | Dibenzylamine compound and medicinal use thereof | |
HUP0102851A2 (hu) | Parazitaellenes artemizinin-származékok (endoperoxidok), eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
HUP0402376A2 (hu) | Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények | |
WO2005092895A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists | |
HUP0302264A2 (hu) | Dopamin D3 receptorok modulátoraiként felhasználható tetrahidrobenzazepin-származékok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0200310A2 (hu) | Triciklikus pirazolszármazékok alkalmazása gyógyszerkészítmények előállítására és az új vegyületek | |
JO2646B1 (en) | New differentiated cyclic compounds as beta - lactam inhibitors | |
DE69503803T2 (de) | 3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament | |
HUP0202001A2 (hu) | DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok | |
IL157179A0 (en) | Fused heterocyclic compounds | |
IL164007A (en) | Compounds and pharmaceutical compositions inhibiting histone deacetylase, their use and process for their manufacture | |
HUP9902471A2 (hu) | Piperazin- és piperidinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
WO2003024967A3 (en) | Indolizines as kinase protein inhibitors | |
HUP0303891A2 (hu) | Gyógyhatású piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
NO20072605L (no) | Nytt antranilinsyrederivat eller et salt derav | |
EA200801134A1 (ru) | Замещенные бициклические пиримидоновые производные | |
EA200601235A1 (ru) | Производные тиазола | |
TW200505922A (en) | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | |
NZ505220A (en) | Arylpiperazines having activity at the serotonin 1A receptor, processes for their preparation and intermediates | |
IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
MX2009004884A (es) | Derivados 8-piperidinil-2-piridinil-pirimido [1,2-a] pirimidin-6-ona y 8-piperidinil-2-pirimidinil-pirimido [1,2-a] pirimidin-6-ona sustuidos. | |
HUP0301458A2 (hu) | Benzoxazinonszármazékok, eljárás előállításukra és a vegyületek felhasználása |